Preferred Label : mRNA-derived KRAS-targeted Vaccine V941;
NCIt synonyms : mRNA-5671 Vaccine;
NCIt definition : A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four
of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential
immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived
KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting
cells (APCs). Following translation, the epitopes are presented via major histocompatibility
complex (MHC) molecules on the surface of the APCs. This leads to an induction of
both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that
specifically target and destroy tumor cells harboring these specific KRAS mutations.
KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types.
It plays a key role in tumor cell proliferation and survival and is associated with
tumor initiation, metastasis and poor prognosis.;
Molecule name : V 941; V941; mRNA-5671; mRNA 5671;
NCI Metathesaurus CUI : CL970771;
Origin ID : C162186;
UMLS CUI : C5206404;
Semantic type(s)
- concept_is_in_subset
- has_target
